Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001104659-22-028838
Filing Date
2022-03-02
Accepted
2022-03-01 18:31:47
Documents
16
Period of Report
2021-12-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-K/A tm227978d1_10ka.htm   iXBRL 10-K/A 82395
2 EXHIBIT 23.1 tm227978d1_ex23-1.htm EX-23.1 1910
3 EXHIBIT 31.1 tm227978d1_ex31-1.htm EX-31.1 9012
4 EXHIBIT 31.2 tm227978d1_ex31-2.htm EX-31.2 8493
5 EXHIBIT 32.1 tm227978d1_ex32-1.htm EX-32.1 5195
  Complete submission text file 0001104659-22-028838.txt   334490

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA akro-20211231.xsd EX-101.SCH 3030
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE akro-20211231_lab.xml EX-101.LAB 36509
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE akro-20211231_pre.xml EX-101.PRE 23996
10 EXTRACTED XBRL INSTANCE DOCUMENT tm227978d1_10ka_htm.xml XML 5660
Mailing Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080
Business Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080 650-487-6488
Akero Therapeutics, Inc. (Filer) CIK: 0001744659 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-38944 | Film No.: 22700394
SIC: 2834 Pharmaceutical Preparations